Genetics, Neurology, Behavior, and Diet in Dementia

Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries. Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.

Part I: Genetics, molecular and cellular biology

1. The neuron navigator 2 gene and Alzheimer’s diseaseChun Xu, Brenda Bin Su, Stephanie Lozano and Kesheng Wang

2. Interlinking polymorphisms, estrogens, and Alzheimer diseaseLu Hua Chen, Leung Wing Chu and You-Qiang Song

3. Linking EEGs, Alzheimer disease, and the phosphatidylinositol-binding clathrin assembly protein (PICALM) geneNatalya Ponomareva, Tatiana Andreeva, Vitaly Fokin, Sergey Illarioshkin and Evgeny Rogaev

4. CD36 gene polymorphisms and Alzheimer’s diseaseOmar Šerý, Nandu Goswami and Vladimir J. Balcar

5. Genetic contributions to sporadic frontotemporal dementiaJessie S. Carr, Daniel W. Sirkis and Jennifer S. Yokoyama

6. Clinical response to cholinesterase inhibitors in dementia: the role of CYP2D6 and APOE genetic polymorphismsLuís Felipe José Ravic de Miranda, Karina Braga Gomes and Paulo Caramelli

7. A1 and A2 purinergic receptor expression in dementiaJ. Mendiola-Precoma, L.C. Berumen, A. Rodríguez-Cruz and G. García-Alcocer

8. Molecular aspects of metallothioneins in dementiasGemma Comes, Anna Escrig, Yasmina Manso, Olaya Fernández-Gayol, Paula Sanchis, Amalia Molinero, Mercedes Giralt, Javier Carrasco and Juan Hidalgo

9. Implication of microRNAs in Alzheimer’s disease pathogenesisKatarzyn Marta Zoltowska, Katarzyna Laskowska-Kaszub, Siranjeevi Nagaraj and Urszula Wojda

10. Role of cellular oxidative stress in dementiaGiovanna Galliciotti, Antonella De Jaco, Diego Sepulveda-Falla, Emanuela D’Acunto and Elena Miranda

11. Toward an integrative understanding of the neuroinflammatory molecular milieu in Alzheimer disease neurodegenerationJuan M. Zolezzi, Paulina Villaseca and Nibaldo C. Inestrosa

12. Wnt signaling and dementiaCarolina Alquezár and Ángeles Martín-Requero

13. Linkage of atypical protein kinase C to Alzheimer diseaseRobert V. Farese and Mini P. Sajan

14. Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer’s diseaseAna Garcia-Osta and Mar Cuadrado-Tejedor

15. Nuclear factor erythroid 2-related factor 2 in Alzheimer’s diseaseKelsey E. Murphy and Joshua J. Park

16. Implications of alpha- and beta-secretase expression and function in Alzheimer’s diseaseSven Reinhardt and Kristina Endres

17. Methylation analysis of DNA in Alzheimer’s diseaseFabio Coppedè

18. The signalosome malfunctions in age-associated neuropathologiesRicardo Puertas-Avendaño, David Quinto-Alemany, Miriam González-Gómez and Raquel Marin

19. FAM3C in Alzheimer’s disease: a risk-related molecule and potential therapeutic targetMasaki Nishimura, Naoki Watanabe, Emi Hibino, Masaki Nakano, Yachiyo Mitsuishi, Lei Liu and Takuma Sugi

20. Amylin and amylin receptors in Alzheimer’s diseaseWen Fu and Jack H. Jhamandas

21. Mammalian target of rapamycin complexes: regulation and Alzheimer’s diseaseHenry Querfurth and Han-Kyu Lee

22. Mammalian target of rapamycin complexes: protein synthesis and autophagy, Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementiaHenry Querfurth and Han-Kyu Lee

23. Linking CD200 in brains and dementia: molecular aspects of neuroinflammationDouglas Gordon Walker

Part II: Neurological, physiological and imaging

24. Hippocampal atrophy associated with dementia risk factors and dementiaHiroshi Yao, Yuko Araki, Fumio Yamashita, Makoto Sasaki and Manabu Hashimoto

25. Inflammation and insulin resistance in Alzheimer’s disease: partners in crimeYuval Nash and Dan Frenke

26. Brain susceptibility to hypoxia/hypoxemia and metabolic dysfunction in Alzheimer’s disease: insights from animal and in vitro modelsVito Antonio Baldassarro, Andrea Bighinati, Michele Sannia, Luciana Giardino and Laura Calzà

27. Neuropeptides and neurolipids: what they are and how they relate to Alzheimer’s diseaseIván Manuel, Laura Lombardero, Alberto Llorente-Ovejero and Rafael Rodríguez-Puertas

28. Neurotransmitter receptors in Alzheimer’s disease: from glutamatergic to cholinergic receptorsLaura Lombardero, Alberto Llorente-Ovejero, Iván Manuel and Rafael Rodríguez-Puertas

29. Aß42-a7-like nicotinic acetylcholine receptors and Alzheimer’s diseaseHoau-Yan Wang and Amber Khan

30. Synaptosomal bioenergetic defects in Alzheimer’s diseasePamela V. Martino Adami and Laura Morelli

31. Limitations of amyloid imaging in Alzheimer’s diseaseDavid Weidman

32. Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer diseaseDmitriy A. Yablonskiy, Tammie L. Benzinger and John C. Morris

33. Hypertensive disorders during pregnancy and later dementia: is there a connection?Ellika Andolf

34. Unraveling the contributions of sleep dysfunction to Alzheimer’s diseaseElie Gottlieb, Natalie A. Grima, Mark Howard, Amy Brodtmann and Matthew P. Pase

Part III: Behaviour and psychopathology

35. Overview of behaviors in dementiaDorothy M. Grillo and Rachel Anderson

36. Delirium superimposed on dementia: a clinical challenge from diagnosis to treatmentMorandi Alessandro, Pozzi Christian, Grossi Eleonora and Bellelli Giuseppe

37. Self-consciousness deficits in dementiaEva M. Arroyo-Anlló and Roger Gil

38. Attentional impairments to novel images in dementiaCelina S. Liu, Michael Rosen, Nathan Herrmann and Krista L. Lanctôt

39. Frontal lobe syndrome and dementiasPetronilla Battista, Chiara Griseta, Rosa Capozzo, Madia Lozupone, Rodolfo Sardone, Francesco Panza and Giancarlo Logroscino

40. The stigma of dementiaAlbert Aboseif and Benjamin K.P. Woo

41. Delusions in dementiasMadia Lozupone, Maddalena La Montagna, Antonello Bellomo, Petronilla Battista, Davide Seripa, Antonio Daniele, Antonio Greco, Onofrio Resta, Giancarlo Logroscino and Francesco Panza

42. Linking motor speech function and dementiaMatthew L. Poole and Adam P. Vogel

43. Spatial navigation and Alzheimer’s diseaseLaura E. Berkowitz, Ryan E. Harvey and Benjamin J. Clark

44. Violence and dementiaG. Cipriani, S. Danti, A. Nuti, L. Picchi and M. Di Fiorino

45. Factors contributing to protection and vulnerability in dementia caregiversFan Zhang, Sheung-Tak Cheng and Manuel Gonçalves-Pereira

Part IV: Diet, nutrition and environment

46. Nutritional status of dementia and management using dietary taurine supplementationMi Ae Bae and Kyung Ja Chang

47. Selenium and Alzheimer’s diseaseAdriana Gisele Hertzog da Silva Leme and Barbara R. Cardoso

48. Linking adiponectin and obesity in dementiaMa1gorzata Bednarska-Makaruk

49. The impact of the gut microbiome in Alzheimer’s disease: cause or consequence?Malena dos Santos Guilherme and Kristina Endres

50. (-)-Epigallocatechin-3-gallate and Alzheimer’s diseaseLaura Xicota and Rafael de la Torre

51. Lead, cadmium and Alzheimer’s diseaseKelly M. Bakulski, Howard Hu and Sung Kyun Park

Part V: Models and modelling in dementia

52. Alzheimer model 5xfad mice and applications to dementia: transgenic mouse models, a focus on neuroinflammation, microglia, and food-derived componentsTatsuhiro Ayabe and Yasuhisa Ano

53. Use of 192 IgG-saporin as a model of dementia and its applicationJ.W. Chang and Y.S. Park

54. Amyloid beta 1e42-induced animal model of dementia: a reviewJosiane Budni and Jade de Oliveira

55. Resources for the neuroscience of dementiaRajkumar Rajendram and Victor R. Preedy